Now showing items 1-8 of 8

    • Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma 

      Wu, Xin-Qi; Marmarelis, Melina Elpi; Hodi, Frank Stephen (Public Library of Science, 2013)
      Heat shock protein 90 (HSP90) is involved in the regulation of diverse biological processes such as cell signaling, proliferation and survival, and has been recently recognized as a potential target for cancer therapy. ...
    • Alpha-CTLA-4 mAb-associated Panenteritis: A Histologic and Immunohistochemical Analysis 

      Oble, Darryl A.; Mino-Kenudson, Mari; Goldsmith, Jeffrey David; Hodi, Frank Stephen; Seliem, Rania M.; Dranoff, Glenn; Mihm, Martin Charles; Hasserjian, Robert Paul; Lauwers, Gregory Y. (Ovid Technologies (Wolters Kluwer Health), 2008)
      Monoclonal antibodies (mAbs) against the cytotoxic T lymphocyte antigen-4 (CTLA-4) molecule are used as an adjuvant to experimental tumor immunization protocols in the treatment of malignant melanomas and ovarian cancers. ...
    • Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy 

      Nishino, Mizuki; Sholl, Lynette Marie; Hatabu, Hiroto; Ramaiya, Nikhil; Hodi, Frank Stephen (New England Journal of Medicine (NEJM/MMS), 2015)
      The use of antibodies against programmed cell death 1 (PD-1), which block inhibitory T-cell checkpoints, is a promising new therapy for advanced cancers.1 Recent trials have shown substantial clinical activity of anti–PD-1 ...
    • Application of Protein Microarrays for Multiplexed Detection of Antibodies to Tumor Antigens in Breast Cancer 

      Anderson, Karen S.; Ramachandran, Niroshan; Wong, Jessica; Raphael, Jacob V.; Hainsworth, Eugenie; Demirkan, Gokhan; Cramer, Daniel William; Aronzon, Dina; Hodi, Frank Stephen; Harris, Lyndsay; Logvinenko, Tanya; LaBaer, Joshua (American Chemical Society (ACS), 2008)
      There is strong preclinical evidence that cancer, including breast cancer, undergoes immune surveillance. This continual monitoring, by both the innate and the adaptive immune systems, recognizes changes in protein expression, ...
    • Defining the Critical Hurdles in Cancer Immunotherapy 

      Fox, Bernard A; Schendel, Dolores J; Butterfield, Lisa H; Aamdal, Steinar; Allison, James P; Ascierto, Paolo Antonio; Atkins, Michael B; Bartunkova, Jirina; Bergmann, Lothar; Berinstein, Neil; Bonorino, Cristina C; Borden, Ernest; Bramson, Jonathan L; Britten, Cedrik M; Cao, Xuetao; Carson, William E; Chang, Alfred E; Characiejus, Dainius; Coukos, George; de Gruijl, Tanja; Dillman, Robert O; Dolstra, Harry; Durrant, Lindy G; Finke, James H; Galon, Jerome; Gollob, Jared A; Gouttefangeas, Cécile; Grizzi, Fabio; Guida, Michele; Håkansson, Leif; Hege, Kristen; Herberman, Ronald B; Hoos, Axel; Huber, Christoph; Hwu, Patrick; Imai, Kohzoh; Jaffee, Elizabeth M; Janetzki, Sylvia; June, Carl H; Kalinski, Pawel; Kaufman, Howard L; Kawakami, Koji; Kawakami, Yutaka; Keilholtz, Ulrich; Khleif, Samir N; Kiessling, Rolf; Kotlan, Beatrix; Kroemer, Guido; Lapointe, Rejean; Levitsky, Hyam I; Lotze, Michael T; Maccalli, Cristina; Maio, Michele; Marschner, Jens-Peter; Mastrangelo, Michael J; Masucci, Giuseppe; Melero, Ignacio; Melief, Cornelius; Nelson, Brad; Nicolini, Andrea; Nishimura, Michael I; Odunsi, Kunle; Ohashi, Pamela S; O'Donnell-Tormey, Jill; Old, Lloyd J; Ottensmeier, Christian; Papamichail, Michael; Parmiani, Giorgio; Pawelec, Graham; Proietti, Enrico; Qin, Shukui; Rees, Robert; Ribas, Antoni; Ridolfi, Ruggero; Ritter, Gerd; Rivoltini, Licia; Romero, Pedro J; Salem, Mohamed L; Scheper, Rik J; Seliger, Barbara; Sharma, Padmanee; Shiku, Hiroshi; Singh-Jasuja, Harpreet; Song, Wenru; Straten, Per Thor; Tahara, Hideaki; Tian, Zhigang; van Der Burg, Sjoerd H; von Hoegen, Paul; Wang, Ena; Welters, Marij JP; Winter, Hauke; Withington, Tara; Wolchok, Jedd D; Xiao, Weihua; Zitvogel, Laurence; Zwierzina, Heinz; Marincola, Francesco M; Gajewski, Thomas F; Wigginton, Jon M; Disis, Mary L; Choudhury, A. Raja; Dranoff, Glenn; Hodi, Frank Stephen; Murphy, William J. (BioMed Central, 2011)
      Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific ...
    • Immunity to the Melanoma Inhibitor of Apoptosis Protein (ML-IAP; livin) in Patients with Malignant Melanoma 

      Zhou, Jun; Yuen, Noah K.; Zhan, Qian; Velazquez, Elsa F.; Murphy, George Francis; Giobbie-Hurder, Anita; Hodi, Frank Stephen (Springer-Verlag, 2011)
      Therapeutic targeting of melanoma antigens frequently focuses on the melanocyte differentiation or cancer-testis families. Antigen-loss variants can often result, as these antigens are not critical for tumor cell survival. ...
    • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation 

      Van Allen, Eliezer Mendel; Golay, H. G.; Liu, Yan; Koyama, S.; Wong, Kwok-Kin; Taylor-Weiner, Amaro; Giannakis, Marios; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, Lynette Marie; Carter, Scott Lambert; Oxnard, Geoffrey Raymond; Janne, Pasi Antero; Getz, Gad A; Lindeman, Neal I.; Hammerman, Peter Seth; Garraway, Levi Alexander; Hodi, Frank Stephen; Rodig, Scott J.; Dranoff, G; Wong, Kwok-Kin; Barbie, David Allen (American Association for Cancer Research (AACR), 2015)
      PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. ...
    • The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma 

      Wu, Xinqiang; Zhu, Meijun; Fletcher, Jonathan A.; Giobbie-Hurder, Anita; Hodi, Frank Stephen (Public Library of Science, 2012)
      GNAQ mutations at codon 209 have been recently identified in approximately 50% of uveal melanomas (UM) and are reported to be oncogenic through activating the MAPK/Erk1/2 pathway. Protein kinase C (PKC) is a component of ...